Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy
Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy
复制标题
高单剂量隔日泼尼松龙治疗治疗多发性肌炎的长期结果
DOI：
10.1159/000338474
复制
发表时间：
2012
影响因子：
2.4
通讯作者：
Makoto Uchino
中科院分区：
文献类型：
--
作者：
Tanaka;A.;et al;Makoto Uchino
BackgroundWe previously reported no difference in the efficacies of high-dose alternate-day (ADT) and daily-dose (DDT) prednisolone therapies in myositis patients, but that the incidence of side effects was lower in the former. The aim of the present study was to compare the long-term outcomes of both treatments in polymyositis patients.MethodsWe compared clinical courses, efficacies, adverse reactions, and outcomes of 115 consecutive, biopsy-proven polymyositis patients treated between 1970 and 2008 with ADT (32 patients) or DDT (83 patients).ResultsMean onset ages, disease severity, incidences of malignancy, and response rates did not differ between the ADT and DDT groups. Adverse reactions (incidence of diabetes) were significantly higher in the DDT group. In this group, the incidences of hyperlipidemia, infection, hypertension, and psychiatric symptoms were also slightly higher, but not significantly so. The 20-year survival rate of the ADT group (68%) was significantly higher (p= 0.0112) than that of the DDT group (37%).ConclusionADT might be useful as an initial treatment option for polymyositis.
